Cleveland Clinic's 20th Annual ASH Review

http://www.clevelandclinicmeded.com/live/courses/ashreview/

 

Malignant Hematology
07:01

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hematological Malignancies and Increases With Aging

FEATURING Hetty E. Carraway
  • 21 views
  • April 14, 2020
26:41

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HMT Are Emerging and May Become Basis of New Backbone Therapy for Pts With MDS and AML

FEATURING Hetty E. Carraway
  • 26 views
  • April 14, 2020
14:17

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Anemia in Myelofibrosis: Luspatercept Improvement in Those Receiving and Not Receiving RBC Transfusions, More Profound Effects in Pts Treated With Ruxolitinib

FEATURING Sudipto Mukherjee
  • 18 views
  • April 14, 2020
14:51

Cleveland Clinic's 20th Annual ASH Review

ASH 2019 Review on Treating Myelofibrosis in the Setting of Thrombocytopenia: Why Paucity of Platelets Translates to Paucity of Treatment?

FEATURING Sudipto Mukherjee
  • 20 views
  • April 14, 2020
06:37

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Limited Stage DLBCL: Can We Use PET Scan to Tailor the Treatment for Early Stage Disease?

FEATURING Brian Hill
  • 533 views
  • April 14, 2020
  • 2
08:38

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on R/R DLBCL: For Frail Unfit Patients, Addition of Polatuzumab Vedotin to BR Is Tolerable and Improves ORR, CR, PFS and OS

FEATURING Brian Hill
  • 124 views
  • April 14, 2020
  • 1
08:35

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on MCL: Can Anti-CD19 CAR-T Cell Therapy Be Used for Mantle Cell Lymphoma Patients After BTK Inhibitor Failure?

FEATURING Brian Hill
  • 164 views
  • April 14, 2020
  • 1
06:19

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Is There a Role for FCR in 2020 and for Which Pts? Does E1912 Suggest Ibrutinib Can Be Considered a Time Limited Therapy?

FEATURING Anthony R. Mato
  • 343 views
  • April 14, 2020
07:59

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review of Frontline CLL: Can We Improve CIT by Adding a Novel Agent to the Backbone? How Can Next Generation BTKis Distinguish Themselves from Ibrutinib?

FEATURING Anthony R. Mato
  • 174 views
  • April 14, 2020
05:08

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Combinations or Sequences of Targeted Agents in CLL: Ibrutinib + Venetoclax for the 1st-Line Treatment - Should MRD Status at EOT Be Driving Treatment Decisions?

FEATURING Anthony R. Mato
  • 78 views
  • April 14, 2020
04:52

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Venetoclax in the R/R CLL: With Additional Follow Up, Is This Regimen Holding up to the Promise of a Time Limited Therapy With Durable Remissions?

FEATURING Anthony R. Mato
  • 27 views
  • April 14, 2020
08:21

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Overcoming BTKi Resistance in CLL: Era of Non-Covalent BTKis? Role of Cellular Therapies

FEATURING Anthony R. Mato
  • 32 views
  • April 14, 2020
11:26

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review: Should High-risk Smoldering Myeloma Be Treated? Evidence for “Watch and Wait” vs. Treat

FEATURING Faiz Anwer
  • 21 views
  • April 14, 2020
05:49

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Newly Diagnosed Multiple Myeloma: VRD-Dara vs. VRD - What Is the Benefit of Daratumumab Addition to 3 Drug Regimen?

FEATURING Faiz Anwer
  • 82 views
  • April 14, 2020
06:21

Cleveland Clinic's 20th Annual ASH Review

2019 ASH Review on Relapsed/Refractory: CAR T Cells - A New Frontier in Immunotherapy & Venetoclax for t(11:14), High BCL2 MM

FEATURING Faiz Anwer
  • 122 views
  • April 14, 2020
  • 1